ReviewCurrent opinion in allergy and clinical immunology2025
Age-dependent differences in anaphylaxis: elderly population.
Review in Current opinion in allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAnaphylaxis in elderly is a little-known topic, despite the worldwide growth of this part of the population. In this review, the main elicitors are discussed, with a particular regard for risk factors, clinical manifestation and management of anaphylaxis in people over 65 years of age. RECENT
findingsAvailable data report age-dependent differences regarding elicitors, cofactors and symptoms of anaphylaxis. In the last years, few studies have focused on anaphylaxis in the elderly, highlighting drugs and insect venom as main triggers. SUMMARY: Drugs and insect venom represent the main triggers of anaphylaxis in individuals over 65 years of age. In addition, idiopathic anaphylaxis is seen more frequently in adults and older adults, and recent studies show an increasing rate of food-related anaphylaxis in this population.Elderly patients are at a greater risk of severe or fatal reactions because they often have multiple comorbidities requiring the concomitant use of several drugs. This may complicate anaphylaxis management, leading to poor outcomes, increased hospitalization and higher admission to intensive care unit.The clinical presentation of anaphylaxis in older adults is most often characterized by cardiovascular symptoms, with syncope as the most frequent one.The injection of adrenaline is the most important treatment of anaphylaxis at any age, and no absolute contraindications are reported. Despite this, its use still remains suboptimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.